RxDoctor Payments Data

William Hawkins, MD

Otolaryngology · Tulsa, OKNPI 1154310555

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.0% of the total across 164 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 19.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $742 and has fallen 57.5% since, to $315 in 2025.

$3,572in general payments, 2019–2025

Across 164 payments — averaging $21.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$712
  • Regeneron Healthcare Solutions, Inc.$692
  • Intersect ENT, Inc.$655
  • Optinose US, Inc.$335
  • Arbor Pharmaceuticals, Inc.$219
  • Stryker$170
  • plus $789 from 13 others
$99,259in research payments, 2019–2025

Across 108 payments — averaging $919.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$37K
  • Sanofi US Services Inc.$36K
  • Sanofi$26K

What the payments were for

  • Food & beverage$3,53899%
  • Education$341%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,572 in reported general payments places this provider in the 80th percentile of 109 otolaryngology providers in Oklahoma.

See all otolaryngology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$76,198
Medicare patients
365
Services billed
710

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth30$5,763
Dexlansoprazole DrDexlansoprazole18$4,144
Ipratropium Bromide68$1,859
Omeprazole103$1,278
Fluticasone Propionate23$502
Mometasone Furoate12$234
Doxycycline Hyclate23$205
Ibuprofen17$121
Methylprednisolone11$92
Gabapentin12$80
Azithromycin18$76
Prednisone17$70
Montelukast Sodium13$65
Famotidine12$36

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →